Rivaroxaban, an oral factor Xa inhibitor, demonstrated recently in the ROCKET-AF trial noninferiority to warfarin in stroke and systemic embolism (21% reduction) without significant difference in the risk of major bleeding [35]. The gene discussed is F10; the disease is atrial fibrillation.